1Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 up- date on diagnosis, risk stratification, and management [ J ]. Am J He- matol, 2013, 88(3): 285-293.
2Najfeld V, Mantella L, Scalise A, et al. Exploring polyeythemia vera with fluorescence in situ hybridization : additional cryptic 9p is the most frequent abnormality detected [ J ]. Br J Haematol, 2002, 119 ( 2 ) : 558 -566.
3Alper S L. Familial renal tubular acidosis[J]. J Nephrol, 2010, 23 ( Suppl 16 ) : $57 - $76.
4Wagner S, Vogel R, Lietzke R, et al. Immunochemical characteriza- tion of a band 3-like anion exchanger in collecting duct of human kid- ney[J]. Am J Physiol, 1987, 253(2 Pt 2) : F213 - F221.
5Fu G H, Wang Y, Xi Y H, et al. Direct interaction and cooperative role of tumor suppressor p16 with band 3 (AE1) [ J]. FEBS Lett, 2005, 579(10) : 2105 -2110.
5Passamonti F, Rumi E, Pungolino E, et al.Life expectancy and prognostic factors for survival in patients with,polycythemia vera and essential thrombocythemia[J].Am J Med, 2004, 117(10): 755-761.
7Group Italiano Studio Policitemia.Low-dose aspirin in polycythemia vera: A pilot study[J].Br J Haematol, 1997, 97(6) : 453-457.
8Chung J, Park P G, Song K I.IgA nephropathy in a patient with polyeythemia vera.Clinical manifestation of chronic renal failure and heavy proteinuria[J].Am J Nephrol, 2002, 115(4): 397-401.
